Skip to main content

Oxicam NSAIDs, Modafinil/Armodafinil, Sulfamothoxazole and Severe Cutaneous Adverse Reaction (SCAR) Events

    Basic Details
    Date Posted
    Medical Product
    Health Outcome(s)
    severe cutaneous adverse reaction (SCAR)

    Modular program-based one-time assessment of Severe Cutaneous Adverse Reaction (SCAR) events among incident users of three different drug classes and drugs, including oxicam NSAIDs, modafinil/armodafinil, and sulfamothoxazole, in the Mini-Sentinel Distributed Datebase. Two main categories of counts were generated: 1) incident counts with respect to each of the medications, and 2) frequency of SCAR events for each exposure group per 1000 person-days at risk [January 2000 – May 2011]. Modular programs are adaptable standardized programs. Results were generated using Modular Program 3; click here for more information. Programs were executed in July 2011.

    If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to

    The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

    Additional Details
    FDA Center
    Time Period
    2000 - 2011
    Analysis Type
    Population / Cohort
    All individuals
    Data Sources
    Mini-Sentinel Distributed Database (MSDD)